(rlFN-a2a). given at a dose of 3 x 10' units (U) intramuscularly (IM) daily for 6 months followed by 3 x 10' U IM three times a week for an additional 18 months in a single institution study. All treatment was stopped after 24 months. Sixty-nine percent of patients achieved a partial response, 11 % a minor response, and 3% (one patient) had stable disease. Six patients (17%) did not respond to rlFN-a2a. Two patients (6%) achieved a response but later progressed on treatment. A total of 23 patients completed 2 years of treatment and are evaluable for long-term follow-up at a median of 20 months postcompletion of therapy (range 9 to 32 months). Eleven patients (48%) have had progression of their disease at a median of 10 months H E EFFICACY OF partially purified alfa interferon T (IFN-a) in patients with hairy cell leukemia (HCL) was first reported in 1984 by Quesada et a1.l Shortly thereafter, two recombinant preparations, rIFN-a2a (Roferon-A; Hoffmann-LaRoche Inc, Nutley, N J ) and rIFN-a2b (Intron-A; Schering Corp, Kenilworth, NJ), identical in structure except at amino acid 23, entered clinical trials in the United States and Europe. Within 18 months, a number of investigators confirmed the high response rate.'-" The optimal length of treatment, however, was not established and individual centers have continued therapy for 12, 18, or 24 months without clear endpoints determined. Moreover, only a few studies9.10 have analyzed pretreatment variables associated with response to rIFN-a. This is particularly important now that another active agent, T-deoxycoformycin, has also demonstrated a significant incidence of response.".I2
In 1984, Memorial Hospital began a Phase I1 efficacy trial with rIFN-a2a in patients with HCL. Patients received 3 x lo6 units given by intramuscular (IM) injection daily for 6 months followed by thrice weekly injections for an additional 18 months. All patients stopped therapy after 2 years. We report here the incidence of response to this treatment and the pattern of disease progression observed during and after therapy, and compare it with other rIFN-a trials. Additionally, we attempt to identify patients who have a high probability of responding to rIFN-a2a and analyze posttreatment variables that are associated with a high rate of relapse after completion of therapy.
MATERIALS AND METHODS
Criteria for patient entry in this study included (1) pathologically confirmed hairy cell leukemia on bone marrow biopsy at time of treatment, (2) significant anemia (hemoglobin <10 g/dL), neutropenia (absolute neutrophil count <1,000 cells/pL), leukocytosis (total white blood cell (WBC) count >10,000 with at least 50% hairy cells) or thrombocytopenia (platelets <100,000 cells/pL), (3) normal hepatic and renal function, (4) no prior chemotherapy (including androgens) or radiation therapy within the preceding 4 weeks, and ( 5 ) signed informed consent in accordance with institutional guidelines. Performance status was not Patient eligibility.
(range .5 to 25 months) after treatment was discontinued. Statistical analysis of pretreatment patient characteristics did not reveal any factor(s) associated with a high probability of responding to rlFN-a2a; however, analysis of posttreatment variables measured after 2 years of treatment suggested that a low platelet count was associated with a high rate of disease progression. These findings are compared with other published trials using rlFN-a2b. a similar but not identical rlFN preparation. We conclude that while rlFN-a2a has a high overall response incidence, the rate of disease progression after therapy is discontinued approaches 50%. and that a subset of patients can be identified who are at high risk for recurrence after completing 2 years of treatment. 0 1990 by The American Society of Hematology. a criterion, and no patients were excluded from study because of previous or concurrent infection or other medical conditions. rIFN-cx2a (Roferon-A) was supplied as a lyopholyzed powder (3 x lo6 units per vial) and reconstituted with 1 cc of sterile water. The dose was given as a self-administered intramuscular injection daily for an initial 6 month induction period. Injections were then changed to a three times per week schedule at the same dose for an additional 18 months of maintenance. All treatment was stopped after 2 years.
Patients were seen monthly as outpatients at Memorial SloanKettering Cancer Center (New York, NY). Physical examinations, complete blood counts with differentials, and chemistry panels were performed at that time, and bone marrow aspirate and biopsies were performed initially every 3 to 4 months. After completion of treatment, patients were seen every 1 to 2 months in follow-up with bone marrows performed every 4 to 6 months.
Serum samples were screened for the presence of antibodies against rIFN-cr2a before start of treatment, after the initial 6 month treatment period, and at the end of the 2 year treatment period. Samples were analyzed by solid-phase enzyme immunoassay and if positive, by neutralizing antiviral assays as described previ0us1y.l~
Response criteria. A complete response (CR) required the following: complete absence of hairy cells in a normocellular bone marrow aspirate and biopsy containing at least 35% myeloid 840 BERMAN ET AL precursors on two consecutive samples at least 1 month apart; a hemoglobin count greater than 12 g/dL; a WBC count greater than 3,000 cells/pL with at least 1,500 neutrophils; and a platelet count greater than 100.000 cells/pL. A partial response (PR) was defined as a decrease in the percentage of bone marrow hairy cells by at least 50% with a bone marrow biopsy containing at least 35% myeloid precursors and with peripheral blood parameters as above. A minor response (MR) was defined as a decrease in the percentage of bone marrow hairy cells by greater than SO%, with 25% to 35% bone marrow myeloid precursors present and improvement in any one of the hematologic abnormalities present in the peripheral blood at time of diagnosis. Stable disease (S) was defined as no change in the bone marrow hairy cell infiltrate or percentage of bone marrow myeloid precursors, but stabilization or improvement for at least a 3-month period in any one of the abnormalities in the peripheral blood count present at time of diagnosis.
Progression of disease was defined as a decrease in hemoglobin to less than 10 g/dL without clinical signs of bleeding, an increase in the WBC count to greater than 10,000 cells/pL or a decrease to less than 3,000 cells/pL, a decrease in the absolute neutrophil count to less than 1,500 cells/pL in three consecutive counts, or a decrease in platelets to less than 100,000 cellslpl.
Among the patients who completed 2 years of therapy, time to disease progression was defined as the interval from completion of therapy to any one of the abnormal hematologic parameters listed above. Patients who progressed with disease or died from complications of the disease while on therapy were considered primary failures.
Statistical analysis. Two statistical questions were asked in this study. First, were any pretreatment patient characteristics associated with a high probability of achieving maximum response, which in this trial was a PR? Second, were any posttreatment variables associated with a high rate of relapse after completion of the 2-year treatment program?
A univariate analysis of pretreatment WBC, hemoglobin, platelet count, percent bone marrow hairy cells, history of prior splenectomy, and history of prior drug treatment was performed using the score test statistic based upon the logistic regression model.I4 Any variable that demonstrated a Pvalue <.20 based on the score test statistic was subsequently analyzed in a multivariate analysis using the logistic regression model. All variables that added information to the model at the .OS level of significance as measured by the maximum likelihood ratio test were included in the final model.
Because the time to relapse or death (disease free survival) in our data was compatible with the proportional hazards assumption between groups, the log rank test statistic was used." The following variables were analyzed: history of prior splenectomy or prior drug treatment, posttreatment WBC, hemoglobin, and platelet count, and residual bone marrow hairy cells measured at the end of 2 years of therapy. Any variable that demonstrated a Pvalue ~2 0 based on the log rank test statistic was subsequently analyzed using a Cox proportional hazards regression analysis. All variables that added information at the .05 significance level were included.
Response duration and survival were calculated using the KaplanMeier method.I6
Progression of disease.
RESULTS
Clinical response. Between July, 1984 and July, 1986, 38 patients were entered on this study. Thirty-five patients are evaluable for response. Two patients who had lymphoid infiltrates in the bone marrow did not have HCL on retrospective review and an additional patient was lost to follow-up after 10 weeks of treatment. Response according to prior treatment modality is outlined in Table 2 . Approximately equal proportions of patients achieved a PR, regardless of whether they had undergone prior splenectomy, drug therapy, both, or neither.
Two patients died within 1 month of beginning treatment from complications arising from thrombocytopenia (central nervous system bleed) or neutropenia (overwhelming infection). Four patients did not manifest any significant response to rIFN-a2a and had progression of disease a t 3.5, 5, 11.5, and 12 months, respectively, from start of treatment. Two of the patients who achieved a response (PR a t 6 months and MR at 11 months) later developed progressive disease a t 12 months and 23 months, respectively, despite continuation of therapy as per study design.
No specific clinical characteristics of these eight patients who failed while on treatment are apparent. Seven of these patients were males with a median age of 41 years (range, 33 to 64). Most were newly diagnosed and had presented for treatment within a relatively short time of diagnosis (median 8. 5 months, range 1 to 30), and four patients had undergone prior splenectomy. As described in greater detail below, three of the four primary nonresponders (excluding the two patients who died early in their treatment course) developed detectable levels of neutralizing antibodies to rIFN-a2a while on treatment.
The majority of patients (75%) complained of fevers, chills, myalgias, and malaise that responded to Tylenol and resolved spontaneously within 4 to 6 weeks. Only one patient was taken off rIFN-a2a because of presumed drug Toxicity. related toxicity. This was a 76-year-old woman who had persistent asymptomatic elevation of hepatic transaminases after 1 year of treatment. Treatment was stopped at that time, but the abnormalities have persisted now more than 3 years after discontinuation and are not thought to be related to treatment with rIFWa2a. Duration of response. Twenty three patients completed 2 years of treatment and are evaluable for long-term followup. This includes one patient who did not change over to the three times per week schedule after completing 6 months of daily injections, but remained on daily injections for the full 2 years. The median length of follow-up since completion of therapy for this group is 20 months (range, 9 to 32).
Four patients are not included in the follow-up group for the following reasons: as noted above, one patient was taken off therapy because of presumed interferon toxicity after 1 year of treatment; one patient moved out of the country after 1 year of treatment; one patient was lost to follow-up after completing 2 years of treatment; and one patient died from a small-cell tumor of the pancreas 8 months after finishing treatment.
Eleven of the 23 patients (48%) who completed 2 years of treatment have had progression of their disease a median of 10 months (range, 0.5 to 25) after cessation of all therapy. Eight patients had achieved a PR (median time to PR was 168 days, range 121 to 554), two an MR, and one had stable disease before relapse. Progression was characterized by thrombocytopenia alone in five patients, leukopenia alone in three patients, and leukopenia with serious infectious episodes in three patients. Two patients in this group developed neutralizing antibody titers within the first year of beginning rIFN-a2a but continued to respond to therapy during the treatment period.
Eight patients have restarted rIFN-aZa, two patients Rave begun 2'-deoxycoformycin, and one patient has remained untreated to date. Four of the patients who restarted have had improvement in their peripheral blood counts, although none has recaptured his initial response, and in three patients, it is too soon to determine whether a response will be achieved. One of the patients who began retreatment with rIFN-a2a died from overwhelming sepsis shortly thereafter.
A total of 12 patients, all of whom achieved a PR, have completed 2 years of treatment with rIFN-a2a and have maintained their initial response. The median time to PR in this group was 156 days (range, 71 to 282). No patient in this group developed neutralizing antibodies to rIFN-a2a.
The median duration of response for the entire group of 23 patients who completed 2 years of treatment is 25 months and is shown in Fig 1. Overall survival for all 35 patients is shown in Fig 2 and demonstrates an 86% survival rate. Two patients died within 2 weeks of starting therapy from disease-related complications, one patient who was a primary nonresponder to rIFN-a2a at 12 months died from an infection after treatment with 2'-deoxycoformycin, and one patient died of infection during a reinduction attempt at time of relapse, which was 5 months from completion of the study (month 29). An additional patient died of a second malignancy 8 months after stopping rIFN-a2a (month 32).
Thirty-two of the 35 evaluable patients had at least two samples analyzed for the presence of neutralizing antibodies to rIFN-a2a. A total of six patients developed positive titers, three of whom were primary nonresponders. As outlined in Table 3 , the antibody titers varied greatly among the six positive patients. Additionally, titers varied within the same patient when values were measured serially. For example, patient 2 had a drop in titer followed by a rise while on a three times per week injection schedule. Patient 3 had a rise in titer off all therapy; of interest is that the titer increased markedly after a short reinduction attempt 30 months later. Patient 4 had monthly fluctuations in his titer while on a daily injection schedule. Patient 5 had a positive titer that subsequently became negative as did Patient 6, who had a low initial titer. The median time from start of therapy to antibody formation was 7.5 months, range 6 to 16.
The score test suggested that initial WBC and prior splenectomy were prognostic factors for achieving a PR ( variables had a P > .05, neither was considered an important prognostic variable for achieving PR.
The log rank test was used to determine whether any prognostic factor, when analyzed individually, had an effect on remission duration. Five factors-history of prior drug therapy, WBC count, hemoglobin, platelets, and percent of residual hairy cells in a bone marrow sample performed after 2 years of therapy-met the cut off criteria (P < .20) based on the log rank test statistic (Table 4) . However, further analysis suggested that one patient with an extremely high percent of residual marrow hairy cells had an overly influen- tial effect on the log rank statistic relative to the other values (n = 22). Upon removal of this one value, percent residual marrow hairy cells no longer met the cutoff criteria. In this instance, the use of case deletion provided a more accurate interpretation of the bulk of our observation^.'^.'^ Cox's proportional hazards model was used to analyze the remaining four factors. This multivariate analysis separated platelet count from pretreatment drug therapy, white blood cell count, and hemoglobin, as the latter variables did not add further information to the model. Figure 3 predicts the disease free survival for a given posttreatment platelet count as derived from the Cox proportional hazards model.'' The curve begins to plateau at 25 months, which is the time of latest relapse, and predicts that patients with posttreatment platelet counts of less than 160,000 cells/pL after 2 years of therapy will relapse within the following year.
In summary, no pretreatment factor(s) could be associated with the probability of achieving a PR. A low platelet count Table 5 summarizes the results from these three large studies, as well as our own.
Our study was unable to define any pretreatment variable(s) that could be associated with a high probability of achieving a PR. Specifically, none of the variables analyzed, including prior treatment history, splenectomy, initial WBC count, hemoglobin, platelet count, and percent hairy cells in the initial bone marrow, predicted response. However, Golomb et all0 have reported that splenectomized patients appear to have a higher response rate to rIFN-a2b than do patients who have spleens in place at time of treatment. In that study, 96 of 115 splenectomized patients (83%) achieved either a complete or partial response compared with 8 of 13 nonsple-.oo llo~oo 22i.oo 33d. oo d.oo 5w:oo nectomized patients (62%). While Quesada et a1' did not after completing 2 years of rIFN-a2a was associated with an increased risk of disease progression.
DISCUSSION
The overall incidence of response on this study (80%) compares favorably with that reported by other large groups.*-' Most patients in our study achieved a PR, and no patient achieved a CR. This is in general agreement with a large study published by Golomb et al." In this instance, rIFN-a2b was given at a dose of 2 x lo6 units/m2 subcutaneously (SC) three times per week for either 12 or 18 months. While approximately 15% of patients achieved a CR (and 77% a PR), the authors emphasize that a CR marrow CR with rIFN-a2a.
Four patients failed to respond to rIFN-a2a, two patients achieved a response but then progressed while on treatment, and two additional patients died early in the course of therapy. This overall failure rate (23%) is higher than that reported by others. Quesada et al,' for example, used rIFN-a2a at the same dose and schedule as the one reported here but state that no patient in their group of 30 failed to respond to treatment. Ratain et ai9 report a 9% failure rate in a group of 69 patients using rIFN-a2b, and Thompson et a14 report a 5% primary treatment failure using the same preparation and treatment schedule as Ratain.
As noted above, no specific clinical characteristics could be identified among the patients who failed early in the treatment program. It is unlikely that poor pretreatment performance status contributed to the high failure rate in our study. Abbreviation: NS, not stated. 'Results published from a single institution study.
tResults published from a multi-institution study. Ninety patients were entered on this protocol and data were reported on 82. Of these, 40 were randomized to receive 18 mos. of treatment, and 42 were randomized to stop therapy after 1 year. The results shown here are from the group randomized to 18 mos. of treatment. Data were reported on 28 of these 40 patients randomized to 18 mos. of treatment.
$Shering preparation (Intron-A). §Hoffman-LaRoche preparation (Roferon-A).
lbalculated total dose assuming average body surface area of 1.7 m2.
YEstimated median time to disease progression based on the assumption that all patients will progress.
Only one of the 35 patients was critically ill at the start of treatment: this was a 33-year-old man with disseminated M avium intracellulare. In contrast to the report by Maziarz et al?' treatment with rIFN-a2a did not halt progression of his infection and he expired within 2 weeks of starting therapy.
One possible explanation for this relatively high failure rate is the incidence of neutralizing antibody formation. This is a complex issue, however, as route of administration, sampling time relative to drug administration, differences in interferon preparation, and the assay method used have all been implicated in the percentage of positive antibody titers reported. In our study, neutralizing antibodies to rIFN-a2a were detected in 6 of 32 patients studied (19%), which is similar to the incidence reported by Steis et a1.22 In their review, 16 of 51 patients (31%) treated with rIFN-a2a with an induction schedule similar to ours developed neutralizing antibodies. However, only 6 of 16 patients (31%) in their study manifested clinical resistance to rIFN-a2a, while in our study, all patients demonstrated some form of resistance to therapy: three patients were primary nonresponders, one patient achieved a PR but then progressed, and two patients relapsed after completing the 2-year treatment course (Table  3) . It is, nonetheless, important to note that nine patients who were antibody negative also relapsed after therapy was discontinued.
The incidence of neutralizing antibody development in patients who have received rIFN-a2b for HCL is not clearly established. Spiegel et a123 initially reported that none of 75 patients tested using the immunoradiometric assay for antibody detection had positive titers; however, subsequent comparison by Itri et all3 of this method and the solid-phase enzyme immunoassay as used in this study has demonstrated that the immunoradiometric assay is less sensitive. In the Itri study, 48 of 100 samples that had tested positive in both the solid phase immunoassay and the interferon anti-viral neutralization assay tested negative in the immunoradiometric assay. More recently, Spiegel et a1 have reported that samples tested using both the enzyme immunoassay and the viral neutalization assay were found to have a very low incidence of antibody formation.24 Nonetheless, clinically meaningful titers have been reported in patients who have received rIFN-a2b for other malignancies. Freund et a125 found antibody titres in 8 of 27 patients with chronic myelogenous leukemia treated with rIFN-a2b at a dose of 5 x lo6 units subcutaneously three times per week; all eight patients either relapsed or proved to have refractory disease. Similarly, Oberg et a126 report that 3 of 20 patients with carcinoid tumors treated with rIFN-a2b at a mean dose of 6 x lo6 units subcutaneously three times per week developed positive titers; two of these patients lost their initial response and one patient had progressive disease despite treatment. Thus, while it may be difficult to compare the incidence of neutralizing antibody formation with each rIFN-a preparation given the differences in dose, schedule, timepoints of measurement, and technical assay variations, the significance of a positive antibody titer appears to be the same; ie, these patients may not respond to therapy with rIFN-a or be at high risk for relapse.
The wide variations in antibody titer observed in this study are similar to those reported by Steis et al." In that study, one patient's titer fluctuated threefold while on a three times per week injection schedule, and another had a progressive drop in titer on an increasing dose schedule. It is not clear why such variations occur. As noted, sampling time after rIFN-a2a injection may affect the titer and, in the absence of specific collection time points, may be responsible for the variations noted in these two studies.
The median time to progression of disease among our group of 11 patients was 10 months and is similar to that reported by Golomb et aIz0 and Quesada et a1,8 which were 6.5 and 6 months, respectively (Table 5 ). Ratain et a19 used a Kaplan-Meier plot to calculate the median time to relapse among their entire group of patients. This median, 25.4 months, is based on the assumption that all patients will eventually relapse and therefore cannot be directly compared with the other relapse rates. Based on the results in the three previously published reports and the data presented in this current study, some preliminary observations can be made. First, the majority of patients achieve a PR that appears to be independent of rIFN-a preparation, schedule administration, or total dose given. Second, half of the patients who relapse will do so within 1 year of completion of therapy. This does not appear to be related to the rIFN-a preparation or the schedule of administration. Third, while the disease free survival after 2 years of treatment on our protocol is shorter than that reported after 1 year of rIFN-a2b? it should not necessarily be concluded that longer periods of treatment are less beneficial. Rather, one can conclude that additional therapy with rIFN-a2a beyond 1 year does not appear to prolong response duration. In this regard, it will be important to evaluate the long-term results of Quesada et al's 1 year study using rIFN-a2a8 and Golomb et al's 18 month study using rIFN-a2b."
It is also apparent from Table 5 that a subset of patients will have a long-term remission after 12, 18, or 24 months of therapy. In an attempt to identify patients at high risk for relapse after completing 2 years of rIFN-aZa, we performed a multivariate analysis analyzing six posttreatment variables. We recognize that our study is limited given its relatively small number of patients; nonetheless, the Cox proportional hazards regression analysis suggested that a low platelet count at the end of 2 years of treatment was associated with a high relapse rate (Fig 3) . In a similar type of analysis, Ratain et a19 demonstrated that the percent of residual hairy cell leukemia in the bone marrow after treatment and a high neutrophil acid phosphatase (NAP) score were important variables for relapse.
It is of interest to note that in this study, despite its 2-year treatment course, no patient developed a chronic fatigue syndrome as reported by Golomb et a1 using . ' 
